Protected by Patent-Linkage System, door of ‘Micardis Plus’ generic market opens

Published: 2016-02-05 14:40:23

Updated: 2016-02-05 14:40:23

Domestic medium pharmaceutical companies have succeeded in avoiding the formulation patent of Micardis Plus(Boehringer Ingelheim), an antihypertensive complex.

The patent has been an obstacle for its generics to enter the market after the enforcement of the Patent-Linkage System last year.

According to the industry on the 3^rd, Withus Pharmaceutical filed a trial for confirmation of the scope ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.